LONDON - Stem cell innovation in the UK is at risk because of structural and cultural barriers that stand in the way of translating products into clinical use. (BioWorld International)

No Abstract BioWorld International CorrespondentKeyNeurotek Pharmaceuticals AG completed a second closing of an internal Series C round, raising the total value of the deal to €8.2 million (US$10.9 million).Although no new investors bought into the company, all its "main existing investors" did participate, Magdeburg, Germany-based KeyNeurotek said.Those include Munich-based Deutsche Venture Capital, IBG Beteiligungsgesellschaft, of Magdeburg, and Bonn-based KfW.